



# 2014 ONCOLOGY DRUG REPORT

World's Largest Active Resource for Decision Making

Oncology  
**COMPANIES**

Cancer  
**MOLECULES**

Cancer  
**INDICATIONS**

Clinical  
**COMPANIES**

Preclinical  
**COMPANIES**

Discovery  
**COMPANIES**

## Content:

<i>Foreword</i> .....	<b>4</b>
<i>List of Figures</i> .....	<b>13</b>
<i>List of Tables</i> .....	<b>17</b>
<i>List of Boxes</i> .....	<b>21</b>
<i>List of Clinical Companies</i> .....	<b>22</b>
<i>List of Pre-clinical Companies</i> .....	<b>27</b>
<i>List of Discovery Companies</i> .....	<b>28</b>
<i>Executive Summary</i> .....	<b>31</b>

## Section A : Oncology Companies with Active Drug Development Pipeline - Infographics

- ***Worldwide Distribution of Companies with Active Cancer Drug Pipeline*** **34**
  - Quantitative Estimation of Cancer Drug Developers present in U.S.A vs. Europe vs. Asia vs. Canada vs. Australia vs. Rest of the World (931 Companies)
  - Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in U.S.A (468 companies)
  - Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Europe (270 companies)
  - Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Asia (132 companies)
- ***Country-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in Europe and Asia Region.*** **35**
  - To identify best and emerging countries, for promoting cancer drug development in the region.
- ***State-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in U.S.A.*** **36**
  - To explore the Top cancer innovation supporting States in United States.
- ***Distribution of 931 companies, on the basis of year of Establishment*** **37**
  - To explore the emergence of Cancer Drug Discovery And Development.
- ***Quantitative Estimation of Oncology Drug Developers on the basis of Human Resource Employed.*** **38**
  - Top 10 cancer drug development companies (in terms of employee numbers), with their total employees vs. total number of R&D staff for past three consecutive years.

<b>Section B : Active Oncology Drugs and Targets in Development - Key Intelligence</b>	<b>39</b>
<ul style="list-style-type: none"> <li>□ <b><i>Distribution of Oncology Molecules in Clinical Development</i></b> (2237 molecules) <b>40</b> <ul style="list-style-type: none"> <li>Total number of Small, Biologics and Non Biological complex molecules in clinical development.</li> <li>Total number of cancer molecules in development in USA, Europe, Asia and Rest of the World.</li> <li>Molecule development strategies - Top 10 companies vs. remaining 921 companies.</li> </ul> </li> <li>□ <b><i>Top 20 Oncology Drug Development Companies</i></b> (In terms of molecules in Clinical Development) <b>42</b> <ul style="list-style-type: none"> <li>Top 20 Cancer clinical development companies, their molecule types (small, biologics &amp; NBCM), clinical phases and total Indications of development.</li> </ul> </li> <li>□ <b><i>Monoclonal Antibodies in Clinical Development</i></b> (173 molecules) <b>44</b> <ul style="list-style-type: none"> <li>Monoclonal antibodies in clinical development with developer and partner name, antibody target, isotype and drug development indications.</li> </ul> </li> <li>□ <b><i>Monoclonal Antibodies in Pre-Clinical Development</i></b> (193 molecules) <b>49</b> <ul style="list-style-type: none"> <li>Monoclonal antibodies in preclinical &amp; discovery development with developer name, antibody target and drug development indications.</li> </ul> </li> <li>□ <b><i>Cancer Vaccines in Clinical Development</i></b> (134 molecules) <b>52</b> <ul style="list-style-type: none"> <li>Cancer Vaccines in clinical development with short description, developer and partner name, drug target and development Indications.</li> </ul> </li> <li>□ <b><i>Cancer Vaccines in Pre-Clinical Development</i></b> (50 molecules) <b>58</b> <ul style="list-style-type: none"> <li>Cancer Vaccines in Pre-clinical &amp; Discovery development with developer name, drug target and development Indications.</li> </ul> </li> <li>□ <b><i>Cancer Targeting Antibodies Drug Conjugates in Clinical Development</i></b> (42 molecules) <b>59</b> <ul style="list-style-type: none"> <li>ADCs in clinical development, with short description of antibody and toxin attached; developer and partner name; its target and development Indications.</li> </ul> </li> <li>□ <b><i>Cancer Targeting Radio-Immuno Conjugates in Clinical Development</i></b> (10 molecules) <b>61</b> <ul style="list-style-type: none"> <li>Radio-Immuno Conjugates in clinical development, with short description of antibody and radio isotope attached; developer and partner name; its target and development Indications.</li> </ul> </li> <li>□ <b><i>Cancer Targeting Recombinant/Fusion Protein Therapies in Development</i></b> (49 molecules) <b>62</b> <ul style="list-style-type: none"> <li>Recombinant/Fusion Protein in clinical development with short description, developer and partner name, their targets and development Indications.</li> </ul> </li> <li>□ <b><i>Cancer Targeting Synthetic Peptides in Clinical Development</i></b> (19 molecules) <b>64</b> <ul style="list-style-type: none"> <li>Synthetic peptides/proteins in clinical development with short description, developer and partner name, their targets and development Indications.</li> </ul> </li> <li>□ <b><i>Oncolytic Virus Based/Gene Therapies in Clinical Development</i></b> (33 molecules) <b>65</b> <ul style="list-style-type: none"> <li>Oncolytic virus based Therapies in clinical development with short description, its developer and partner name; drug target and development Indications.</li> </ul> </li> <li>□ <b><i>Cell Based Therapies for cancer treatment in Clinical Development</i></b> (19 molecules) <b>67</b> <ul style="list-style-type: none"> <li>T-Cell, Stem Cell and Other Cell based therapies in clinical development with short description, its developer and partner name; drug target and development Indications.</li> </ul> </li> <li>□ <b><i>Other Biological Therapies in Clinical Development</i></b> (23 molecules) <b>68</b> <ul style="list-style-type: none"> <li>Remaining biological therapies in clinical development for cancer treatment, with short description, their developer and partner name; drug target and development Indications.</li> </ul> </li> </ul>	

□ <b><i>Protein Kinases – An Emerging Class of Cancer Drug Targets</i></b>	<b>69</b>
<p>Protein kinases vs other cancer drug targets in clinical development;          Comparative developmental profile of protein kinases, with their molecules and indications numbers.          Top four kinases classes targeting cancer with their molecule numbers;          Cancer targeting kinases development strategies - Top 10 companies vs. Remaining 921 companies.          Established kinases in cancer drug discovery, their FDA approval years; Annual sales and indications.          Anticipated protein kinases launch In 2014-15, with cancer indications.</p>	
□ <b><i>Complete List of Emerging Cancer Drug Targets (228 Targets)</i></b>	
<p><b>Protein Kinases as Cancer Drug Targets</b> -Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development for the target.  <i>(55 Major Protein Target Classes)</i></p>	<b>72</b>
<p><b>Tumor Necrosis Factors as Cancer Drug Targets</b> -Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development for the target.  <i>(11 Major Protein Targets)</i></p>	<b>80</b>
<p><b>G-coupled Receptors as Cancer Drug Targets</b> -Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development for the target.  <i>(9 Major Protein Targets)</i></p>	<b>82</b>
<p><b>Tumor Surface Antigens as Cancer Drug Targets</b> –Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development for the target.  <i>(22 Major Protein Targets)</i></p>	<b>83</b>
<p><b>Transcription Factors as Cancer Drug Targets</b> –Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development for the target.  <i>(14 Major Protein Targets)</i></p>	<b>85</b>
<p><b>Targeting Cellular Metabolites as Cancer Drug Targets</b> –Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development for the target.  <i>(14 Major Protein Targets)</i></p>	<b>87</b>
<p><b>Growth Factor as Cancer Drug Targets</b> –Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development.  <i>(8 Major Protein Targets)</i></p>	<b>89</b>
<p><b>Miscellaneous Other Cancer Drug Targets</b> –Target Name, Gene, Protein Family, Cellular Location &amp; Functions, Short Description with drugs in clinical development.  <i>(95 Targets)</i></p>	<b>90</b>

## **Section C : Oncology Indications in various Developmental Stages- *Intelligence*** **103**

□ <b><i>Distribution of Oncology Indications in Clinical Development (4264 indications)</i></b>	<b>104</b>
<p>Division of 4264 indications for 2237 Molecules, in drugs types – Small, Biologic and NBCM.          Geographic distribution of Clinical Indications and its correlation with number of molecules from similar region in development; Phase-Wise Breakup of total Indications;          Cancer Clinical Indications strategies - Top 10 companies vs. remaining 513 companies;          Comparative analysis on the preference of Top 10 companies for Small Molecule Vs. Biologics, in compare to remaining 513 companies.</p>	
□ <b><i>Drug Development Strategies- Top 10 Companies vs. Remaining 921 Companies</i></b>	<b>105</b>
<p>A competitive intelligence de-marking the preference of Large Pharma Majors to Small Innovators - their choice of targets; cancer indications and tyeps of molecules development.</p>	



- ***Drug Development Profile & Pipeline Analysis - Lung Cancer*** **106**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-** NSCLC  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against NSCLC;  
 Top 10 companies *vs.* others strategies in Lung Cancer Drug Development.
- Pipeline Analysis:-** SCLC **114**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Breast Cancer*** **115**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against Breast cancer;  
 Top 10 companies *vs.* others strategies in Breast Cancer Drug Development.
- ***Drug Development Profile & Pipeline Analysis - Colorectal Cancer*** **123**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against Colorectal cancer;  
 Top 10 companies *vs.* others strategies in Colorectal Cancer Drug Development.
- ***Drug Development Profile & Pipeline Analysis - Melanoma Cancer*** **129**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against Melanoma cancer;  
 Top 10 companies *vs.* others strategies in Melanoma Cancer Drug Development.
- Drug Development Pipeline:-** Other Skin Cancers including Non-Melanoma Cancers.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Prostate Cancer*** **136**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against Prostate cancer;  
 Top 10 companies *vs.* others strategies in Prostate Cancer Drug Development.

### □ *Drug Development Profile & Pipeline Analysis - Ovarian Cancer* **143**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against Ovarian cancer;  
 Top 10 companies *vs.* others strategies in Ovarian Cancer Drug Development.

### **Drug Development Pipeline:-** Gynaecologic Malignancies. **149**

Cervical Cancer - Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).  
 Fallopian Tube Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).  
 Peritoneal Cancer - Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).  
 Endometrial Cancer - Detailed Ph III, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

### □ *Drug Development Profile & Pipeline Analysis - Pancreatic Cancer* **151**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Monoclonal Antibodies, Vaccines and other Biologics in development.  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
 Strong Pipeline Companies with highest number of molecules against Pancreatic cancer;  
 Top 10 companies *vs.* others strategies in Pancreatic Cancer Drug Development.

### **Drug Development Pipeline:-** Gastrointestinal Tract Cancers. **157**

Oesophageal Cancer- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).  
 Biliary Tract Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).  
 Gallbladder Cancer - Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).  
 Cholangiocarcinoma -Detailed Ph III, Ph II, Ph I & preclinical Pipeline (including developers, partners & targets).  
 Anal Cancer - Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).  
 Gastrointestinal Stromal Tumor- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

### □ *Drug Development Profile & Pipeline Analysis - Hepatocellular Carcinoma* **158**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

### □ *Drug Development Profile & Pipeline Analysis - Gastric Cancer* **161**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

- ***Drug Development Profile & Pipeline Analysis - Multiple Myeloma*** **163**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Leukemia*** **165**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
**Pipeline Analysis:-** Leukemia  
 Acute Myeloid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Acute Myelogenous Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Acute Lymphoid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Acute Lymphocytic Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Chronic Myeloid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Chronic Myelogenous Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Chronic Myelomonocytic Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.  
 Chronic Lymphoid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
- ***Drug Development Profile & Pipeline Analysis - Non-Hodgkin Lymphoma*** **171**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
**Pipeline Analysis:-** Waldenstrom's Macroglobulinemia  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Hodgkin Lymphoma*** **175**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
**Pipeline Analysis:-**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis- Brain Cancer (including Glioblastoma)*** **176**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
**Pipeline Analysis:- Glioblastoma**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
**Neuroblastoma** - Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).  
**Medulloblastoma** - Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).  
**Anaplastic Astrocytoma**- Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).
- ***Drug Development Profile & Pipeline Analysis- Head & Neck Cancer*** **179**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
**Pipeline Analysis:- Glioblastoma**  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

*Nasopharynx Cancer*- Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).

*Oral Cancer*- Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).

- ***Drug Development Profile & Pipeline Analysis - Renal Cell Carcinoma*** **182**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
*Pipeline Analysis:-*  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).  
*Wilm's Tumor* - Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).
- ***Drug Development Profile & Pipeline Analysis - Bladder Cancer*** **185**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
*Pipeline Analysis:-*  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Thyroid Cancer*** **187**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
*Pipeline Analysis:-*  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Sarcoma*** **189**  
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;  
 Top Selling targeted therapies -their Annual Sales & Forecast;  
*Pipeline Analysis:-*  
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;  
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Other Rare Cancer Indications - Developmental Pipeline*** Detailed PhIII, Ph II, Ph I, Pre clinical & Discovery Pipeline (including developers, partners, targets and indications). **191**
- ***Orphan Drug Status drugs in development for Cancer Treatment*** **192**  
*Name of Drug and Developer, its Orphan drug Indications and Orphan status providing agencies - US FDA and EMEA.*
- ***US FDA New Oncology Drug Approvals - 2013*** **195**  
 Developer, Approval month, Partner, Drug's Proprietary Name, Approved Indication.
- ***Oncology Clinical Pipeline - Major Phase III Failures - 2013*** **196**  
 Ph III Molecules-Key Partners & expected Launch ; Ph II & Ph I Clinical Pipeline (including partners).



## Section D : Individual Oncology Company Profile (with Active Clinical Pipeline) **197**

### □ *A to Z Alphabetical Profiles of Cancer Clinical Drug Developer Companies (523 Companies)*

Individual company Pages includes: **Company Profile** - Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

**Clinical Pipeline Profile**– Drug name, its target description, various development indications for cancer cure with current clinical trials and trials status (Active, Recruiting, Completed etc), FDA/EMEA Orphan drug status, Special Protocol Assessment , fast track approvals etc; company's pre-clinical & discovery pipeline.

**Management Profile** –Address, Contact phone number, e-mail, employees number range, Key Decision Maker (CXOs) names, designation with e-mail & LinkedIn IDs,, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 17th April 2014).

## Section E : Individual Oncology Company Profile (with Active PreClinical Pipeline) **796**

### □ *A to Z Alphabetical Profiles of Cancer Preclinical Drug Developer Companies (360 Companies)*

Individual company Pages includes: **Company Profile** - Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

**Pre-Clinical Pipeline Profile** – Drugs name, its targets, with details of its development for various indications for cancer cure, FDA/EMEA Orphan drug status, company's pre-clinical pipeline.

**Management Profile** –Address, Contact phone number, e-mail, employees number range, key management people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 17th April 2014).

## Section F : Individual Oncology Company Profile (with Active Discovery Pipeline) **1011**

### □ *A to Z Alphabetical Profiles of Cancer Discovery stage Companies (48 Companies)*

Individual company Pages includes: **Company Profile** - Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

**Discovery Pipeline Profile** – Drug name, its targets, with details, of its development for various indications for cancer cure.

**Management Profile** –Address, Contact phone number, e-mail, employees number range, key management people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 17th April 2014).

### *Appendix A: Country Wise List of 931 Companies..... 1038*

### *Appendix B: Complete 2237 Molecules List, along with their Developer's Name..... 1041*

## List of Figures:

### Section A : Oncology Companies with Active Drug Development Pipeline- *Infographics* 33

<b>Figure A.1</b>	Qualitative Estimation of Oncology Drug Developers present in U.S.A vs. Europe vs. Asia vs. Australia vs. Canada vs. Rest of the World (931 Active Companies).	34
<b>Figure A.2</b>	Quantitative Estimation of clinical, preclinical & discovery companies present in <b>U.S.A</b> (468 companies)	34
<b>Figure A.3</b>	Quantitative Estimation of clinical, preclinical & discovery companies present in <b>Europe</b> (270 companies)	34
<b>Figure A.4</b>	Quantitative Estimation of clinical, preclinical & discovery companies present in Asia (132 companies)	34
<b>Figure A.5</b>	Showing all individual <b>19 Countries in Europe</b> and <b>8 Countries in Asia</b> , along with the individual oncology focused companies present in these countries.	35
<b>Figure A.6</b>	Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in <b>Europe</b> Region.	35
<b>Figure A.7</b>	Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in <b>Asia</b> Region.	35
<b>Figure A.8</b>	Showing all individual <b>28 States in U.S.A</b> , along with the individual number of oncology focused companies present in these States.	36
<b>Figure A.9</b>	Bar Graph for State-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in U.S.A	36
<b>Figure A.10</b>	Distribution of Active Cancer Drug Developers on the basis of year of Formation/Incorporation.	37
<b>Figure A.11</b>	Bar Graph showing incorporation pattern of cancer drug developers form 1991 onwards.	37
<b>Figure A.12</b>	Division of 931 cancer drug development companies on the basis of Human Resource employed.	38

### Section B : Active Oncology Drugs & Targets in Development - *Intelligence* 39

<b>Figure B.1</b>	Distribution of Active Cancer Molecules in various Developmental Stages among Small, Biologics & others (2237 Molecules).	40
<b>Figure B.2</b>	Division of total cancer molecules in development among U.S.A, Europe, Asia & Rest of the World.	40
<b>Figure B.3</b>	Molecule Development Strategies:- <b>A.</b> Total molecules in development – Top 10 companies <b>vs.</b> remaining 921 companies. <b>B.</b> Top 10 companies - Small Molecules <b>vs.</b> Biologics. <b>C.</b> Remaining 921 companies - Small Molecules <b>vs.</b> Biologics.	40
<b>Figure B.4</b>	Clinical phase-wise (Ph I/PhII/PhIII), Preclinical & Discovery stage distribution of 2237 molecules.	41
<b>Figure B.5</b>	Phase-wise distribution of <b>Small Molecules</b> in various developmental stages for cancer treatment.	41
<b>Figure B.6</b>	Phase-wise distribution of <b>Biologics</b> in various developmental stages for cancer treatment.	41
<b>Figure B.7</b>	Clinical phase-wise division of cancer molecules in development in U.S.A, Europe, Asia & RoW.	41
<b>Figure B.8</b>	Protein Kinase in cancer drug development <b>A.</b> Total number of Targets in Development – Protein Kinases <b>vs.</b> others. <b>B.</b> Total number of Molecules – Protein Kinases <b>vs.</b> others. <b>C.</b> Clinical phase-wise distribution of Protein Kinases in cancer drug development.	69
<b>Figure B.9</b>	Distribution of total Kinases in cancer clinical development in U.S.A, Europe, Asia & RoW.	69
<b>Figure B.10</b>	Top four Protein Kinases (Targets) in cancer clinical drug development (w.r.t molecules in development).	69
<b>Figure B.11</b>	Top three cancer Indications with highest numbers of Protein Kinases in clinical development.	69
<b>Figure B.12</b>	Protein Kinases Molecules development Strategies:- <b>A.</b> Total Kinases in development – Top 10 companies <b>vs</b> remaining 921 companies. <b>B.</b> Top 10 companies – clinical phase-wise distribution of Protein Kinases. <b>C.</b> Remaining 921 companies - clinical phase wise distribution of Protein Kinases.	69

<b>Section C: Oncology Indications in various Development Stages - Intelligence</b>		<b>103</b>
<b>Figure C.1</b>	Distribution of Total Oncology Indications in various Development (4264 Active Cancer Drug Indications for 2231 Cancer Drugs under development) <b>A.</b> Relative Number of Cancer Drug Indications for Small Molecules vs Biologics vs Others. <b>B.</b> Comparative Clinical, Preclinical & Discovery Indications under development.	<b>104</b>
<b>Figure C.2</b>	Distribution of 4264 cancer drug development indications among USA, Europe, Asia and RoW.	<b>104</b>
<b>Figure C.3</b>	Cancer Clinical Indications <b>Development Strategies:-</b> <b>A.</b> Total indications in clinical trials – Top 10 companies <b>vs</b> remaining 513 companies. <b>B.</b> Top 10 companies clinical pipeline indications – Small Molecules <b>vs</b> Biologics. <b>C.</b> Remaining 513 companies clinical pipeline indications - Small Molecules <b>vs</b> Biologics <b>vs</b> NBCM.	<b>104</b>
<b>Figure C.4</b>	Global incidence of <b>Lung Cancer</b> .	<b>106</b>
<b>Figure C.5</b>	<b>A.</b> Lung Cancer treatment molecules <b>vs.</b> total number of molecules in various development stages for cancer treatment. <b>B.</b> Companies with active drug development pipeline for Lung Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	<b>109</b>
<b>Figure C.6</b>	Exploring Lung Cancer <b>Development Strategies:-</b> <b>A.</b> Comparison between Top 10 Companies, Lung cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules. <b>B.</b> Percentage of molecules in development for Lung Cancer, between U.S.A <b>vs.</b> Europe <b>vs.</b> RoW.	<b>109</b>
<b>Figure C.7</b>	<b>A.</b> Phase-wise division of total Lung Cancer molecules in various developmental stages. <b>B.</b> Subtype division of Lung Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> . <b>C.</b> Subtype division of Lung Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	<b>109</b>
<b>Figure C.8</b>	<b>A.</b> Distribution of Lung Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> . <b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics among PhI, II, III &amp; Preclinical/ Discovery</i> development phases.	<b>110</b>
<b>Figure C.9</b>	Global incidence of <b>Breast Cancer</b> .	<b>115</b>
<b>Figure C.10</b>	<b>A.</b> Breast Cancer treatment molecules <b>vs.</b> total number of molecules in various development stages for cancer treatment. <b>B.</b> Companies with active drug development pipeline for Breast Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	<b>118</b>
<b>Figure C.11</b>	Exploring Breast Cancer <b>Development Strategies:-</b> <b>A.</b> Comparison between Top 10 Companies, Breast cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules. <b>B.</b> Percentage of molecules in development for Breast Cancer, between USA <b>vs.</b> Europe <b>vs.</b> RoW.	<b>118</b>
<b>Figure C.12</b>	<b>A.</b> Phase-wise division of total Breast Cancer molecules in various developmental stages. <b>B.</b> Subtype division of Breast Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> . <b>C.</b> Subtype division of Breast Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	<b>118</b>
<b>Figure C.13</b>	<b>A.</b> Distribution of Breast Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> . <b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics among PhI, II, III &amp; Preclinical/ Discovery</i> development phases.	<b>119</b>
<b>Figure C.14</b>	Global incidence of <b>Colorectal Cancer</b> .	<b>123</b>
<b>Figure C.15</b>	<b>A.</b> Colorectal Cancer treatment molecules <b>vs.</b> total number of molecules in various development stages for cancer treatment. <b>B.</b> Companies with active drug development pipeline for Colorectal Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	<b>125</b>

<b>Figure C.16</b>	Exploring Colorectal Cancer <b>Development Strategies:-</b>	<b>125</b>
	<b>A.</b> Comparison between Top 10 Companies, Colorectal cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules.	
	<b>B.</b> Percentage of molecules in development for Colorectal Cancer among USA <b>vs.</b> Europe <b>vs.</b> RoW.	
<b>Figure C.17</b>	<b>A.</b> Phase-wise division of total Colorectal Cancer molecules in various developmental stages.	<b>125</b>
	<b>B.</b> Subtype division of Colorectal Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
	<b>C.</b> Subtype division of Colorectal Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
<b>Figure C.18</b>	<b>A.</b> Distribution of Colorectal Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> .	<b>126</b>
	<b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics</i> among <i>PhI, II, III &amp; Pre clinical/ Discovery</i> development phases.	
<b>Figure C.19</b>	Global incidence of <b>Melanoma Cancer.</b>	<b>129</b>
<b>Figure C.20</b>	<b>A.</b> Melanoma Cancer treatment molecules <b>vs.</b> total number of molecules in various development stages for cancer treatment.	<b>131</b>
	<b>B.</b> Companies with active drug development pipeline for Melanoma Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	
<b>Figure C.21</b>	Exploring Melanoma Cancer <b>Development Strategies:-</b>	<b>131</b>
	<b>A.</b> Comparison between Top 10 Companies, Melanoma cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules.	
	<b>B.</b> Percentage of molecules in development for Lung Cancer, between USA <b>vs.</b> Europe <b>vs.</b> RoW.	
<b>Figure C.22</b>	<b>A.</b> Phase-wise division of total Melanoma Cancer molecules in various developmental stages.	<b>131</b>
	<b>B.</b> Subtype division of Melanoma Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
	<b>C.</b> Subtype division of Melanoma Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
<b>Figure C.23</b>	<b>A.</b> Distribution of Melanoma Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> .	<b>132</b>
	<b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics</i> among <i>PhI, II, III &amp; Preclinical/ Discovery</i> development phases.	
<b>Figure C.24</b>	Global incidence of <b>Prostate Cancer.</b>	<b>136</b>
<b>Figure C.25</b>	<b>A.</b> Prostate Cancer treatment molecules <b>vs.</b> total number of molecules in various development stages for cancer treatment.	<b>138</b>
	<b>B.</b> Companies with active drug development pipeline for Prostate Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	
<b>Figure C.26</b>	Exploring Prostate Cancer <b>Development Strategies:-</b>	<b>138</b>
	<b>A.</b> Comparison between Top 10 Companies, Prostate cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules.	
	<b>B.</b> Percentage of molecules in development for Prostate Cancer, between USA <b>vs.</b> Europe <b>vs.</b> RoW.	
<b>Figure C.27</b>	<b>A.</b> Phase-wise division of total Prostate Cancer molecules in various developmental stages.	<b>138</b>
	<b>B.</b> Subtype division of Prostate Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; Others</i> .	
	<b>C.</b> Subtype division of Prostate Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; Others</i> .	
<b>Figure C.28</b>	<b>A.</b> Distribution of Prostate Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> .	<b>139</b>
	<b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics</i> among <i>PhI, II, III &amp; Preclinical/ Discovery</i> development phases.	
<b>Figure C.29</b>	Global incidence of <b>Ovarian Cancer.</b>	<b>143</b>
<b>Figure C.30</b>	<b>A.</b> Ovarian Cancer treatment molecules <b>vs.</b> total number of molecules in various developmental stages for cancer treatment.	<b>145</b>
	<b>B.</b> Companies with active drug development pipeline for Ovarian Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	



<b>Figure C.31</b>	Exploring Ovarian Cancer <b>Development Strategies:-</b>	<b>145</b>
	<b>A.</b> Comparison between Top 10 Companies, Ovarian cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules.	
	<b>B.</b> Percentage of molecules in development for Ovarian Cancer, between USA <b>vs.</b> Europe <b>vs.</b> RoW.	
<b>Figure C.32</b>	<b>A.</b> Phase-wise division of total Ovarian Cancer molecules in various developmental stages.	<b>145</b>
	<b>B.</b> Subtype division of Ovarian Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
	<b>C.</b> Subtype division of Ovarian Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
<b>Figure C.33</b>	<b>A.</b> Distribution of Ovarian Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> .	<b>146</b>
	<b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics among PhI, II, III &amp; Preclinical/ Discovery</i> development phases.	
<b>Figure C.34</b>	Global incidence of <b>Pancreatic Cancer.</b>	<b>151</b>
<b>Figure C.35</b>	<b>A.</b> Pancreatic Cancer treatment molecules <b>vs.</b> total number of molecules in various developmental stages for cancer treatment.	<b>153</b>
	<b>B.</b> Companies with active drug development pipeline for Pancreatic Cancer treatment <b>vs.</b> total number of companies worldwide, with cancer drug pipeline.	
<b>Figure C.36</b>	Exploring Pancreatic Cancer <b>Development Strategies:-</b>	<b>153</b>
	<b>A.</b> Comparison between Top 10 Companies, Pancreatic cancer clinical pipeline <b>vs.</b> remaining other clinical companies pipeline molecules.	
	<b>B.</b> Percentage of molecules in development for Pancreatic Cancer, between USA <b>vs.</b> Europe <b>vs.</b> RoW.	
<b>Figure C.37</b>	<b>A.</b> Phase-wise division of total Pancreatic Cancer molecules in various development stages.	<b>153</b>
	<b>B.</b> Subtype division of Pancreatic Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
	<b>C.</b> Subtype division of Pancreatic Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics &amp; NBCM</i> .	
<b>Figure C.38</b>	<b>A.</b> Distribution of Pancreatic Cancer Pipeline in <i>Small, Biologics &amp; NBCM</i> .	<b>154</b>
	<b>B.</b> Distribution of <i>Vaccines, Monoclonal Antibodies &amp; other Biologics among PhI, II, III &amp; Preclinical/ Discovery</i> development phases.	
<b>Figure C.39</b>	Global incidence of <b>Hepatocellular Carcinoma.</b>	<b>158</b>
<b>Figure C.40</b>	Global incidence of <b>Gastric Cancer.</b>	<b>161</b>
<b>Figure C.41</b>	Global incidence of <b>Multiple Myeloma.</b>	<b>163</b>
<b>Figure C.42</b>	Global incidence of <b>Leukemia.</b>	<b>165</b>
<b>Figure C.43</b>	Global incidence of <b>Non-Hodgkin Lymphoma.</b>	<b>171</b>
<b>Figure C.44</b>	Global incidence of <b>Hodgkin Lymphoma.</b>	<b>175</b>
<b>Figure C.45</b>	Global incidence of <b>Brain Cancer including Glioblastoma.</b>	<b>176</b>
<b>Figure C.46</b>	Global incidence of <b>Head &amp; Neck Cancer.</b>	<b>179</b>
<b>Figure C.47</b>	Global incidence of <b>Renal Cell Carcinoma.</b>	<b>182</b>
<b>Figure C.48</b>	Global incidence of <b>Bladder Cancer.</b>	<b>185</b>
<b>Figure C.49</b>	Global incidence of <b>Thyroid Cancer.</b>	<b>187</b>

## List of Tables:

### Section A : Oncology Companies with Active Drug Development Pipeline- *Infographics* 31

<b>Table A.1</b>	Top 10 Cancer drug development companies (in terms of employee number).	<b>38</b>
------------------	---	-----------

### Section B : Active Oncology Drugs & Targets in Development - *Intelligence* 39

<b>Table B.1</b>	Top 20 companies with highest number of cancer clinical molecules in development.	<b>42</b>
<b>Table B.2</b>	Monoclonal Antibodies in Clinical Trials (174 Molecules- their developer, partner, target, isotypes & indications).	<b>43</b>
<b>Table B.3</b>	Monoclonal Antibodies in Preclinical & Discovery stage (193 Molecules- their developer, target & indications).	<b>49</b>
<b>Table B.4</b>	Cancer Vaccines in Clinical development (134 Vaccines-their developer, partner, target, indications & comments).	<b>52</b>
<b>Table B.5</b>	Cancer Vaccines in Preclinical & Discovery development stage (50 Vaccines-their developer, target & indications).	<b>58</b>
<b>Table B.6</b>	Antibody Drug Conjugates in Clinical development (42 Molecules, developer, partner, target, indications & comments).	<b>59</b>
<b>Table B.7</b>	Radio-Immuno Conjugates in Clinical Development (10 Molecules, developer, partner, target, indications, comments).	<b>61</b>
<b>Table B.8</b>	Recombinant/Fusion Proteins based therapies in Clinical Development (49 Molecules, developer, partner, target, indications, comments).	<b>62</b>
<b>Table B.9</b>	Synthetic Peptides based therapies in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).	<b>64</b>
<b>Table B.10</b>	Gene Therapies & Oncolytic based therapies in Clinical Development (33 Molecules, developer, partner, target, indications, comments).	<b>65</b>
<b>Table B.11</b>	T cell based therapies in Clinical Trials (8 Molecules, developer, partner, target, indications, comments).	<b>67</b>
<b>Table B.12</b>	Stem cell based therapies in Clinical Trials (6 Molecules, developer, partner, target, indications, comments).	<b>67</b>
<b>Table B.13</b>	Other cell based therapies in Clinical Trials (5 Molecules, developer, partner, target, indications, comments).	<b>67</b>
<b>Table B.14</b>	Miscellaneous other Biologics in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).	<b>68</b>
<b>Table B.15</b>	Approved Kinase Inhibitors for Cancer Cure (Developer, type, target, approved since, 2013 sales, indications).	<b>70</b>
<b>Table B.16</b>	Expected New Kinases Launches in 2014-15 (Drug, developer, type, target, expected launch & indication).	<b>71</b>
<b>Table B.17</b>	Cancer Drug Targets - Protein Kinases (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's description).	<b>72</b>
<b>Table B.18</b>	Cancer Drug Targets - Tumor Necrosis Factor Family (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	<b>80</b>
<b>Table B.19</b>	Cancer Drug Targets - G-coupled Protein Receptors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	<b>82</b>
<b>Table B.20</b>	Cancer Drug Targets - Tumor Antigens (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	<b>83</b>
<b>Table B.21</b>	Cancer Drug Targets - Transcription Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	<b>85</b>
<b>Table B.22</b>	Cancer Drug Targets - Metabolic Enzymes (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	<b>87</b>
<b>Table B.23</b>	Cancer Drug Targets - Growth Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).	<b>89</b>
<b>Table B.24</b>	Cancer Drug Targets - Miscellaneous other Targets (individual target name, Gene, protein family, Drugs in development for the target, target Description).	<b>90</b>

### Section C: Oncology Indications in various Development Stages - *Intelligence* 103

<b>Table C.1</b>	Molecule Development Strategies - Top 10 companies Vs. Remaining 921 companies (Comparison between total molecules, clinical phases, types, top 7 targets, top 9 indications and market capitalization).	<b>105</b>
<b>Table C.2</b>	Top selling chemotherapies for Lung Cancer.	<b>107</b>
<b>Table C.3</b>	Top selling targeted therapies for Lung Cancer.	<b>107</b>
<b>Table C.4</b>	Molecules in Ph III clinical trials for NSCLC (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>108</b>

<b>Table C.5</b>	Monoclonal Antibodies in various drug development stages for the treatment of Lung Cancer.	<b>110</b>
<b>Table C.6</b>	Vaccines in various drug development stages for the treatment of Lung Cancer.	<b>110</b>
<b>Table C.7</b>	Miscellaneous other Biologics in various drug development stages for the treatment of Lung Cancer.	<b>111</b>
<b>Table C.8</b>	<b>Non Small Lung Cancer (NSCLC) Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>111</b>
<b>Table C.9</b>	Molecules in Ph III clinical trials for Lung Cancer ( <b>SCLC</b> ) (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>114</b>
<b>Table C.10</b>	<b>Small Cell Lung Cancer (SCLC) Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>114</b>
<b>Table C.11</b>	Top selling Chemotherapies/Hormonal Therapies for <b>Breast Cancer</b> .	<b>116</b>
<b>Table C.12</b>	Top selling Targeted Therapies for Breast Cancer.	<b>116</b>
<b>Table C.13</b>	Molecules in Ph III clinical trials for Breast Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>117</b>
<b>Table C.14</b>	Monoclonal Antibodies in various drug development stages for the treatment of Breast Cancer.	<b>119</b>
<b>Table C.15</b>	Vaccines in various drug development stages for the treatment of Breast Cancer.	<b>119</b>
<b>Table C.16</b>	Miscellaneous other Biologics in various drug development stages for the treatment of Breast Cancer.	<b>120</b>
<b>Table C.17</b>	<b>Breast Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>120</b>
<b>Table C.18</b>	Top selling chemotherapies for <b>Colorectal Cancer</b> .	<b>124</b>
<b>Table C.19</b>	Top selling targeted therapies for Colorectal Cancer.	<b>124</b>
<b>Table C.20</b>	Molecules in Ph III clinical trials for Colorectal Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>124</b>
<b>Table C.21</b>	Monoclonal Antibodies in various drug development stages for the treatment of Colorectal Cancer.	<b>126</b>
<b>Table C.22</b>	Vaccines in various drug development stages for the treatment of Colorectal Cancer.	<b>126</b>
<b>Table C.23</b>	Miscellaneous other Biologics in drug development stages for the treatment of Colorectal Cancer.	<b>127</b>
<b>Table C.24</b>	<b>Colorectal Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>127</b>
<b>Table C.25</b>	Top selling chemotherapies for <b>Melanoma Cancer</b> .	<b>130</b>
<b>Table C.26</b>	Top selling targeted therapies for Melanoma Cancer.	<b>130</b>
<b>Table C.27</b>	Molecules in Ph III clinical trials for Melanoma Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>130</b>
<b>Table C.28</b>	Monoclonal Antibodies in various drug development stages for the treatment of Melanoma Cancer.	<b>132</b>
<b>Table C.29</b>	Vaccines in various drug development stages for the treatment of Melanoma Cancer.	<b>132</b>
<b>Table C.30</b>	Miscellaneous other Biologics in drug development stages for the treatment of Melanoma Cancer.	<b>133</b>
<b>Table C.31</b>	<b>Melanoma Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>134</b>
<b>Table C.32</b>	Other Skin Cancers Including <b>Non-Melanoma Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>135</b>
<b>Table C.33</b>	Top selling Chemotherapies for <b>Prostate Cancer</b> .	<b>137</b>
<b>Table C.34</b>	Top selling Targeted therapies for Prostate Cancer.	<b>137</b>
<b>Table C.35</b>	Molecules in Ph III clinical trials for Prostate Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>137</b>
<b>Table C.36</b>	Monoclonal Antibodies in various drug development stages for the treatment of Prostate Cancer.	<b>139</b>
<b>Table C.37</b>	Vaccines in various drug development stages for the treatment of Prostate Cancer.	<b>139</b>
<b>Table C.38</b>	Miscellaneous other Biologics in drug development stages for the treatment of Prostate Cancer.	<b>140</b>
<b>Table C.39</b>	<b>Prostate Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>140</b>
<b>Table C.40</b>	Top selling chemotherapies for <b>Ovarian Cancer</b> .	<b>144</b>
<b>Table C.41</b>	Molecules in Ph III clinical trials for Ovarian Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>144</b>
<b>Table C.42</b>	Monoclonal Antibodies in various drug development stages for the treatment of Ovarian Cancer.	<b>146</b>
<b>Table C.43</b>	Vaccines in various drug development stages for the treatment of Ovarian Cancer.	<b>146</b>
<b>Table C.44</b>	Miscellaneous other Biologics in drug development stages for the treatment of Ovarian Cancer.	<b>147</b>
<b>Table C.45</b>	<b>Ovarian Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>147</b>

<b>Table C.46</b>	<b><i>Cervical Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>149</b>
<b>Table C.47</b>	<b><i>Fallopian Tube Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>149</b>
<b>Table C.48</b>	<b><i>Peritoneal Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>149</b>
<b>Table C.49</b>	<b><i>Endometrial Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>149</b>
<b>Table C.50</b>	Top selling chemotherapies for <b>Pancreatic Cancer</b> .	<b>152</b>
<b>Table C.51</b>	Top selling targeted therapies for Pancreatic Cancer.	<b>152</b>
<b>Table C.52</b>	Molecules in Ph III clinical trials for Pancreatic Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	<b>152</b>
<b>Table C.53</b>	Monoclonal Antibodies in various drug development stages for the treatment of Pancreatic Cancer.	<b>154</b>
<b>Table C.54</b>	Vaccines in various drug development stages for the treatment of Pancreatic Cancer.	<b>154</b>
<b>Table C.55</b>	Miscellaneous other Biologics in drug development stages for the treatment of Pancreatic Cancer.	<b>155</b>
<b>Table C.56</b>	<b><i>Pancreatic Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>155</b>
<b>Table C.57</b>	<b><i>Neuroendocrine Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>156</b>
<b>Table C.58</b>	<b><i>Esophageal Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.59</b>	<b><i>GastroIntestinal Stromal Tumor Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.60</b>	<b><i>Biliary Tract Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.61</b>	<b><i>GallBladder Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.62</b>	<b><i>Midgut Carcinoid Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.63</b>	<b><i>Cholangiocarcinoma Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.64</b>	<b><i>Anal Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>157</b>
<b>Table C.65</b>	Top selling targeted therapies for <b>Hepatocellular Carcinoma</b> .	<b>159</b>
<b>Table C.66</b>	Molecules in Ph III clinical trials for Hepatocellular Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>159</b>
<b>Table C.67</b>	<b><i>Hepatocellular Carcinoma Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>159</b>
<b>Table C.68</b>	Top selling targeted therapies for <b>Gastric Cancer</b> .	<b>161</b>
<b>Table C.69</b>	Molecules in Ph III clinical trials for <b>Gastric Cancer</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>162</b>
<b>Table C.70</b>	<b><i>Gastric Cancer Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>162</b>
<b>Table C.71</b>	Molecules in Ph III clinical trials for <b>Multiple Myeloma</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>163</b>
<b>Table C.72</b>	<b><i>Multiple Myeloma Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>164</b>
<b>Table C.73</b>	Top selling targeted therapies for <b>Leukemia</b> .	<b>166</b>
<b>Table C.74</b>	Molecules in Ph III clinical trials for Leukemia (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>166</b>
<b>Table C.75</b>	<b><i>Acute Myeloid Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>167</b>
<b>Table C.76</b>	<b><i>Acute Myelogenous Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>168</b>
<b>Table C.77</b>	<b><i>Acute Lymphoid Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>169</b>
<b>Table C.78</b>	<b><i>Acute Lymphocytic Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>169</b>
<b>Table C.79</b>	<b><i>Chronic Myeloid Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>169</b>
<b>Table C.80</b>	<b><i>Chronic Myelogenous Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>169</b>
<b>Table C.81</b>	<b><i>Chronic Myelomonocytic Leukemia Pipeline</i></b> - Clinical stage drugs, developers, partners & targets.	<b>169</b>
<b>Table C.82</b>	<b><i>Chronic Lymphoid Leukemia Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>170</b>
<b>Table C.83</b>	Top selling targeted therapies for <b>Non Hodgkin Lymphoma</b> .	<b>172</b>
<b>Table C.84</b>	Molecules in Ph III clinical trials for Non Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>172</b>
<b>Table C.85</b>	<b><i>Non Hodgkin Lymphoma Pipeline</i></b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>173</b>
<b>Table C.86</b>	Waldenstrom's Macroglobulinemia- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>174</b>



<b>Table C.87</b>	Molecules in Ph III clinical trials for <b>Hodgkin Lymphoma</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>175</b>
<b>Table C.88</b>	<b>Hodgkin Lymphoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>175</b>
<b>Table C.89</b>	Molecules in Ph III clinical trials for <b>Brain Cancer</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>177</b>
<b>Table C.90</b>	<b>Glioblastoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>177</b>
<b>Table C.91</b>	<b>Neuroblastoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>178</b>
<b>Table C.92</b>	<b>Medullolastoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>178</b>
<b>Table C.93</b>	<b>Anaplastic Astrocytoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>178</b>
<b>Table C.94</b>	Top selling targeted therapies for <b>Head &amp; Neck Cancer</b> .	<b>180</b>
<b>Table C.95</b>	Molecules in Ph III clinical trials for <b>Head &amp; Neck Cancer</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>180</b>
<b>Table C.96</b>	<b>Head &amp; Neck Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>180</b>
<b>Table C.97</b>	<b>Nasopharynx Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>181</b>
<b>Table C.98</b>	<b>Oral Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>181</b>
<b>Table C.99</b>	Top selling targeted therapies for <b>Renal Cell Carcinoma</b> .	<b>183</b>
<b>Table C.100</b>	Molecules in Ph III clinical trials for <b>Renal Cell Carcinoma</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>183</b>
<b>Table C.101</b>	<b>Renal Cell Carcinoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>183</b>
<b>Table C.102</b>	<b>Wilm's Tumor Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>184</b>
<b>Table C.103</b>	Top selling targeted therapies for <b>Bladder Cancer</b> .	<b>186</b>
<b>Table C.104</b>	Molecules in Ph III clinical trials for <b>Bladder Cancer</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>186</b>
<b>Table C.105</b>	<b>Bladder Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>186</b>
<b>Table C.106</b>	Top selling targeted therapies for <b>Thyroid Cancer</b> .	<b>188</b>
<b>Table C.107</b>	Molecules in Ph III clinical trials for <b>Thyroid Cancer</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>188</b>
<b>Table C.108</b>	<b>Thyroid Cancer Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>188</b>
<b>Table C.109</b>	Molecules in Ph III clinical trials for <b>Sarcoma</b> (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	<b>189</b>
<b>Table C.110</b>	<b>Sarcoma Pipeline</b> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets).	<b>189</b>
<b>Table C.111</b>	Other Rare Cancer Indications Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	<b>191</b>
<b>Table C.112</b>	Orphan Drug Status cancer molecules in clinical development (145 Molecules with 174 orphan indications) (Drug Name, Phase, Orphan indication, developer, USFDA/EMA approvals).	<b>192</b>
<b>Table C.113</b>	US FDA New Oncology Drug Approvals -2013 (Developer, month of approval, partner, drug proprietary name, established name, approved indications with disease state)	<b>195</b>
<b>Table C.114</b>	Oncology Clinical Pipeline- Major Drug Failures 2013 (Drug, Developer, month, phase, indications, comments).	<b>196</b>

## List of Boxes:

<b>Section C: Oncology Indications in various Development Stages - Intelligence</b>		<b>103</b>
<b>Box C.1</b>	<b>Lung Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>106</b>
<b>Box C.2</b>	Strong Clinical Pipeline Companies - Lung Cancer.	<b>109</b>
<b>Box C.3</b>	<b>Breast Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>115</b>
<b>Box C.4</b>	Strong Clinical Pipeline Companies - Breast Cancer.	<b>118</b>
<b>Box C.5</b>	<b>Colorectal Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>123</b>
<b>Box C.6</b>	Strong Clinical Pipeline Companies - Colorectal Cancer.	<b>125</b>
<b>Box C.7</b>	<b>Melanoma Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>129</b>
<b>Box C.8</b>	Strong Clinical Pipeline Companies - Melanoma Cancer.	<b>131</b>
<b>Box C.9</b>	<b>Prostate Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>136</b>
<b>Box C.10</b>	Strong Clinical Pipeline Companies - Prostate Cancer.	<b>138</b>
<b>Box C.11</b>	<b>Ovarian Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>143</b>
<b>Box C.12</b>	Strong Clinical Pipeline Companies - Ovarian Cancer.	<b>145</b>
<b>Box C.13</b>	Other <b>Gynaecologic Malignancies Indications.</b>	<b>149</b>
<b>Box C.14</b>	<b>Pancreatic Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>151</b>
<b>Box C.15</b>	Strong Clinical Pipeline Companies - Pancreatic Cancer.	<b>153</b>
<b>Box C.16</b>	Other <b>Gastrointestinal Indications.</b>	<b>157</b>
<b>Box C.17</b>	<b>Hepatocellular Carcinoma-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>158</b>
<b>Box C.18</b>	<b>Gastric Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>161</b>
<b>Box C.19</b>	<b>Multiple Myeloma-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>163</b>
<b>Box C.20</b>	<b>Leukemia-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>165</b>
<b>Box C.21</b>	<b>NonHodgkin Lymphoma-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>171</b>
<b>Box C.22</b>	<b>Hodgkin Lymphoma-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>175</b>
<b>Box C.23</b>	<b>Brain Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>176</b>
<b>Box C.24</b>	<b>Head &amp; Neck Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>179</b>
<b>Box C.25</b>	<b>Renal Cell Carcinoma-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>182</b>
<b>Box C.26</b>	<b>Bladder Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>185</b>
<b>Box C.27</b>	<b>Thyroid Cancer-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>187</b>
<b>Box C.28</b>	<b>Sarcoma-</b> An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	<b>189</b>